Clinical laboratory markers of inflammation as determinants of chronic graft-versus-host disease activity and NIH global severity

Leukemia

Volumn 26, Issue 4, 2012, Pages 633-643

  Grkovic, L ^a,b   Baird, K ^a   Steinberg, S M ^a   Williams, K M ^a   Pulanic, D ^b   Cowen, E W ^a   Mitchell, S A ^a   Hakim, F T ^a   Martires, K J ^a   Avila, D N ^a   Taylor, T N ^a   Salit, R B ^a   Rowley, S D ^c   Zhang, D ^a   Fowler, D H ^a   Bishop, M R ^a   Gress, R E ^a   Pavletic, S Z ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b KBC Zagreb   (Croatia)

^c HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

activity; chronic graft versus host disease; CRP; inflammation; platelets

Indexed keywords

ALBUMIN; BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; FERRITIN; HEMOGLOBIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PARATHYROID HORMONE; PREDNISONE;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DISEASE ACTIVITY; DISEASE MARKER; DISEASE SEVERITY; EOSINOPHIL COUNT; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FERRITIN BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NATIONAL HEALTH ORGANIZATION; NEUTROPHIL COUNT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SERUM; SYSTEMIC THERAPY; THROMBOCYTE COUNT; TREATMENT RESPONSE;

EID: 84859652196     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.254     Document Type: Article

References (51)

1. Weisdorf DJ. Chronic graft-versus-host disease: where is promise for the future? Leukemia 2005; 19: 1532-1535. (Pubitemid 43090395)
2. Lee SJ, Klein JP, Barrett AJ, Ringden O, Antin JH, Cahn JY et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood 2002; 100: 406-414. (Pubitemid 34761100)
3. Thepot S, Zhou J, Perrot A, Robin M, Xhaard A, de Latour RP et al. The graft-versus-leukemia effect is mainly restricted to NIH-defined chronic graft-versus-host disease after reduced intensity conditioning before allogeneic stem cell transplantation. Leukemia 2010; 24: 1852-1858.
4. Vogelsang G, Pavletic S. Clinical manifestations and natural history. In: Flowers M, Vogelsang G (eds). Chronic Graft Versus Host Disease Interdisciplinary Management. Cambrige University Press: New York, NY, 2009, pp 56-69.
5. Cho BS, Min CK, Eom KS, Kim YJ, Kim HJ, Lee S et al. Feasibility of NIH consensus criteria for chronic graft-versus-host disease. Leukemia 2009; 23: 78-84.
6. Barak V, Levi-Schaffer F, Nisman B, Nagler A. Cytokine dysregulation in chronic graft versus host disease. Leuk Lymphoma 1995; 17: 169-173.
7. Skert C, Damiani D, Michelutti A, Patriarca F, Arpinati M, Fili C et al. Kinetics of Th1/Th2 cytokines and lymphocyte subsets to predict chronic GVHD after allo-SCT: results of a prospective study. Bone Marrow Transplant 2009; 44: 729-737.
8. Fujii H, Cuvelier G, She K, Aslanian S, Shimizu H, Kariminia A et al. Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children's Oncology Group. Blood 2008; 111: 3276-3285.
9. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340: 448-454. (Pubitemid 29084777)
10. Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant 2003; 9: 215-233. (Pubitemid 40045609)
11. Liem LM, Fibbe WE, van Houwelingen HC, Goulmy E. Serum transforming growth factor-beta1 levels in bone marrow transplant recipients correlate with blood cell counts and chronic graft-versus-host disease. Transplantation 1999; 67: 59-65. (Pubitemid 29061137)
12. Parkman R. Chronic graft-versus-host disease. Curr Opin Hematol 1998; 5: 22-25. (Pubitemid 28122153)
13. Seconi J, Watt V, Ritchie DS. Nephrotic syndrome following allogeneic stem cell transplantation associated with increased production of TNF-alpha and interferon-gamma by donor T cells. Bone Marrow Transplant 2003; 32: 447-450. (Pubitemid 37038858)
14. Mallya RK, de Beer FC, Berry H, Hamilton ED, Mace BE, Pepys MB. Correlation of clinical parameters of disease activity in rheumatoid arthritis with serum concentration of C-reactive protein and erythrocyte sedimentation rate. J Rheumatol 1982; 9: 224-228. (Pubitemid 12014862)
15. Ohtsuka T. Serum interleukin-6 level is reflected in elevated high-sensitivity C-reactive protein level in patients with systemic sclerosis. J Dermatol 2010; 37: 801-806.
16. Glovsky MM. Applications of complement determinations in human disease. Ann Allergy 1994; 72: 477-486; quiz 486-490.
17. Gaitonde S, Samols D, Kushner I. C-reactive protein and systemic lupus erythematosus. Arthritis Rheum 2008; 59: 1814-1820.
18. Schots R, Kaufman L, Van Riet I, Lacor P, Trullemans F, De Waele M et al. Monitoring of C-reactive protein after allogeneic bone marrow transplantation identifies patients at risk of severe transplant-related complications and mortality. Bone Marrow Transplant 1998; 22: 79-85. (Pubitemid 28330540)
19. Pihusch M, Pihusch R, Fraunberger P, Pihusch V, Andreesen R, Kolb HJ et al. Evaluation of C-reactive protein, interleukin-6, and procalcitonin levels in allogeneic hematopoietic stem cell recipients. Eur J Haematol 2006; 76: 93-101.
20. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945-956. (Pubitemid 41754712)
21. Mitchell SA, Leidy NK, Mooney KH, Dudley WN, Beck SL, LaStayo PC et al. Determinants of functional performance in long-term survivors of allogeneic hematopoietic stem cell transplantation with chronic graft-versus-host disease (cGVHD). Bone Marrow Transplant 2010; 45: 762-769.
22. Pavletic SZ, Martin P, Lee SJ, Mitchell S, Jacobsohn D, Cowen EW et al. Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant 2006; 12: 252-266. (Pubitemid 43273710)
23. Lee S, Cook EF, Soiffer R, Antin JH. Development and validation of a scale to measure symptoms of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2002; 8: 444-452.
24. Ware Jr JE, Gandek B. Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project. J Clin Epidemiol 1998; 51: 903-912. (Pubitemid 28527145)
25. Schubert MM, Williams BE, Lloid ME, Donaldson G, Chapko MK. Clinical assessment scale for the rating of oral mucosal changes associated with bone marrow transplantation. Development of an oral mucositis index. Cancer 1992; 69: 2469-2477.
26. Hollander M, Wolfe DA. Nonparametric Statistical Methods, 2nd edn. Wiley: New York, NY, 1999, pp 189-269.
27. Martin PJ, Counts Jr GW, Appelbaum FR, Lee SJ, Sanders JE, Deeg HJ et al. Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. J Clin Oncol 2010; 28: 1011-1016.
28. Martin PJ, Storer BE, Carpenter PA, Couriel DR, Flowers ME, Gupta V et al. Comparison of short-term response and long-term outcomes after initial systemic treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2011; 17: 124-132.
29. Martin PJ, Pavletic SZ. Biology and management of chronic graft-versus-host disease. Cancer Treat Res 2009; 144: 277-298.
30. Lee SJ. Have we made progress in the management of chronic graft-vs-host disease? Best Pract Res Clin Haematol 2010; 23: 529-535.
31. Flowers ME, Storer B, Carpenter P, Rezvani AR, Vigorito AC, Campregher PV et al. Treatment change as a predictor of outcome among patients with classic chronic graft-versus-host disease. Biol Blood Marrow Transplant 2008; 14: 1380-1384.
32. Martin PJ. Study design and endpoints in graft-versus-host disease. Best Pract Res Clin Haematol 2008; 21: 357-372. (Pubitemid 351712721)
33. Woloshin S, Schwartz LM. Distribution of C-reactive protein values in the United States. N Engl J Med 2005; 352: 1611-1613. (Pubitemid 40517111)
34. Macy EM, Hayes TE, Tracy RP. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem 1997; 43: 52-58. (Pubitemid 27024390)
35. Kushner I, Rzewnicki D, Samols D. What does minor elevation of C-reactive protein signify? Am J Med 2006; 119: 166 e117-128.
36. Otterness IG. The value of C-reactive protein measurement in rheumatoid arthritis. Semin Arthritis Rheum 1994; 24: 91-104. (Pubitemid 24326547)
37. Walker SA, Riches PG, Rogers TR, White S, Hobbs JR. Value of serum C-reactive protein measurement in the management of bone marrow transplant recipients. Part II: late post-transplant period. J Clin Pathol 1984; 37: 1022-1026. (Pubitemid 14072280)
38. Rovo A, Daikeler T, Halter J, Heim D, Tsakiris DA, Stern M et al. Late altered organ function in very long-term survivors after allogeneic hematopoietic stem cell transplantation: a paired comparison with their HLA-identical sibling donor. Haematologica 2011; 96: 150-155.
39. Martin PJ. Biology of chronic graft-versus-host disease: implications for a future therapeutic approach. Keio J Med 2008; 57: 177-183.
40. Kaminska D, Bernat B, Vakulenko O, Kuzniar J, Tyran B, Suchnicki K et al. Glomerular lesion and increased cytokine gene expression in renal tissue in patients with decompensated nephrotic syndrome due to chronic GvHD. Ren Fail 2010; 32: 510-514.
41. Colombo AA, Rusconi C, Esposito C, Bernasconi P, Caldera D, Lazzarino M et al. Nephrotic syndrome after allogeneic hematopoietic stem cell transplantation as a late complication of chronic graft-versus-host disease. Transplantation 2006; 81: 1087-1092.
42. Senaldi G, Lupoli S, Vergani D, Black CM. Activation of the complement system in systemic sclerosis. Relationship to clinical severity. Arthritis Rheum 1989; 32: 1262-1267. (Pubitemid 19261077)
43. Socie G, Ritz J, Martin PJ. Current challenges in chronic graft-versus-host disease. Biol Blood Marrow Transplant 2010; 16: S146-S151.
44. Akpek G. Clinical grading in chronic graft-versus-host disease: is it time for change? Leuk Lymphoma 2002; 43: 1211-1220. (Pubitemid 34537965)
45. Pulanic D, Lozier JN, Pavletic SZ. Thrombocytopenia and hemostatic disorders in chronic graft versus host disease. Bone Marrow Transplant 2009; 44: 393-403.
46. Ito H. Anti-interleukin-6 therapy for Crohn's disease. Curr Pharm Des 2003; 9: 295-305. (Pubitemid 36131724)
47. Kaser A, Brandacher G, Steurer W, Kaser S, Offner FA, Zoller H et al. Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis. Blood 2001; 98: 2720-2725.
48. Anscher MS, Peters WP, Reisenbichler H, Petros WP, Jirtle RL. Transforming growth factor beta as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer. N Engl J Med 1993; 328: 1592-1598. (Pubitemid 23151919)
49. Guiducci S, Distler O, Distler JH, Matucci-Cerinic M. Mechanisms of vascular damage in SSc - implications for vascular treatment strategies. Rheumatology (Oxford) 2008; 47(Suppl 5): v18-v20.
50. Imanguli MM, Swaim WD, League SC, Gress RE, Pavletic SZ, Hakim FT. Increased T-bet+ cytotoxic effectors and type I interferon-mediated processes in chronic graft-versus-host disease of the oral mucosa. Blood 2009; 113: 3620-3630.
51. Gergis U, Arnason J, Yantiss R, Shore T, Wissa U, Feldman E et al. Effectiveness and safety of tocilizumab, an anti-interleukin-6 receptor monoclonal antibody, in a patient with refractory GI graft-versus-host disease. J Clin Oncol 2010; 28: e602-e604.